<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01113346</url>
  </required_header>
  <id_info>
    <org_study_id>03/09-AVVA RUS</org_study_id>
    <nct_id>NCT01113346</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Filtrum-STI in Children With Viral Gastroenteritis</brief_title>
  <acronym>F-GE-09</acronym>
  <official_title>Phase II Double Blind Placebo-controled Randomized Comparative Multicentered Study of Efficacy and Safety of Filtrum-STI, 0,4g Tablets (Produced by AVVA RUS) in Children With Viral Gastroenteritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avva Rus, JSC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Vladimir Moscow Children's Clinical Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arhangelsk Regional Children's Clinical Hospital named after Vizshletsov P.G.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Avva Rus, JSC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II double blind multicenter randomized placebo-controled clinical study aimed
      to find out whether treatment with Filtrum-STI (orally administered 0,4g tablets) is safe and
      effective in children with viral gastroenteritis. Filtrum-STI (lignin hydrolytic) is a drug
      with a high absorbing ability, that binds and eliminates toxins, pathogenic microorganisms
      and viruses. Filtrum-STI is inoffensive for mucous membranes, enhances colonic propulsion and
      improves its natural microflora. The drug is not toxic and well combines with other
      medication
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">February 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of gastroenteritis</measure>
    <time_frame>Day 7 after start of the intervention</time_frame>
    <description>It's measured by ordinal scales (4- and 5-scores) using data about patients' body temperature, bloating, nausea, abdominal pain, meteorism, stool frequency (physical examination and parent-reported questionnaire).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intestinal Viruses detection and quantification</measure>
    <time_frame>Day 7 after start of the intervention</time_frame>
    <description>It is measured by PCR laboratory test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secretory IgA</measure>
    <time_frame>Day 7 after start of the intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of gastroenteritis</measure>
    <time_frame>Day 10-14 after end of the intervention</time_frame>
    <description>It's measured by ordinal scales (4- and 5-scores) using data about patients' body temperature, bloating, nausea, abdominal pain, meteorism, stool frequency (physical examination and parent-reported questionnaire).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scatological examination</measure>
    <time_frame>Day 7 after start of the intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scatological examination</measure>
    <time_frame>Day 10-14 after end of the intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dysbacteriosis analysis</measure>
    <time_frame>Day 7 after start of the intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal Viruses detection and quantification</measure>
    <time_frame>Day 10-14 after end of the intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secretory IgA</measure>
    <time_frame>Day 10-14 after end of the intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital functions</measure>
    <time_frame>Days 1,2,3,4,5,6,7 after start of the intervention and day 10-14 after end of one</time_frame>
    <description>It includes Heart rate, Breathing rate, Body temperature.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood test</measure>
    <time_frame>Day 7 after start of the intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical blood analysis</measure>
    <time_frame>Day 7 after start of the intervention</time_frame>
    <description>It includes crude protein, alanine aminotransferase, aspartate aminotransferase, bilirubin, blood urea, creatinine, sodium, potassium, glucose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine analysis</measure>
    <time_frame>Day 7 after start of the intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Viral Gastroenteritis</condition>
  <arm_group>
    <arm_group_label>Filtrum-STI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filtrum-STI (lignin hydrolytic)</intervention_name>
    <description>For children aged less than 1 y.o.: Filtrum-STI, 400mg per day (1/2 tablet 2 times a day) for 7 days.
For children aged 1-4 y.o.: Filtrum-STI, 800mg per day (1 tablet 2 times a day) for 7 days.</description>
    <arm_group_label>Filtrum-STI</arm_group_label>
    <other_name>lignin hydrolytic, sorbent, enterosorbent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>For children aged less than 1 y.o.: Placebo, 1/2 tablet 2 times a day for 7 days.
For children aged 1-4 y.o.: Placebo, 1 tablet 2 times a day for 7 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  children aged 0-4 y.o. diagnosed with moderate viral gastroenteritis;

          -  72 h or less from the onset of gastrointestinal symptoms.

        Exclusion Criteria:

          -  severe diseases;

          -  individual intolerance of Filtrum-STI

          -  treatment with antiviral, immunomodulatory drugs during the study and 2 weeks before
             inclusion

          -  treatment with pre- pro- and antibiotics 2 weeks before inclusion

          -  participation in other clinical study 1 month before inclusion and during
             participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>4 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Meskina, MD, DrSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Vladimir Children's Moscow Clinical Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lyudmila Kobeleva, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Avva Rus, JSC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nickolay A. Kryuchkov, MD, PhD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Avva Rus, JSC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lyudmila Kobeleva, MD, PhD</last_name>
    <phone>+7-495-9567559</phone>
    <email>kobeleva@avva-rus.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nickolay Kryuchkov, MD, PhD, MPH</last_name>
    <phone>+7-495-9567559</phone>
    <email>nkryuchkov@avva-rus.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arhangelsk Regional Children's Clinical Hospital named after P.G. Vizshletsov</name>
      <address>
        <city>Arhangelsk</city>
        <state>Arhangelskaya oblast</state>
        <zip>163062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larisa Titova, MD, PhD</last_name>
      <phone>+7-8182-280433</phone>
      <email>irina-bul@yandex.ru</email>
    </contact>
    <contact_backup>
      <last_name>Olga Samodova, MD, DrSc</last_name>
      <phone>+7-8182-22-95-42</phone>
      <email>samodova@atknet.ru</email>
    </contact_backup>
    <investigator>
      <last_name>Larisa Titova, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olga Samodova, MD, DrSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vladimir Children's Moscow Clinical Hospital</name>
      <address>
        <city>Moscow</city>
        <zip>107014</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Meskina, MD, DrSc</last_name>
      <phone>+7-916-1216172</phone>
      <email>meskinaelena@mail.ru</email>
    </contact>
    <contact_backup>
      <last_name>Lyudmila Feklisova, MD, DrSc</last_name>
      <phone>+7-495-2682226</phone>
      <email>vespamen@yandex.ru</email>
    </contact_backup>
    <investigator>
      <last_name>Lyudmila Feklisova, MD, DrSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Meskina, MD, DrSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2010</study_first_submitted>
  <study_first_submitted_qc>April 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2010</study_first_posted>
  <last_update_submitted>July 13, 2010</last_update_submitted>
  <last_update_submitted_qc>July 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Elena Meskina, MD, DrSc</name_title>
    <organization>St. Vladimir Moscow Children's Clinical Hospital</organization>
  </responsible_party>
  <keyword>enterosorbent</keyword>
  <keyword>sorbent</keyword>
  <keyword>gastrointestinal decontamination</keyword>
  <keyword>viral diarrhea</keyword>
  <keyword>rotavirus</keyword>
  <keyword>Filtrum</keyword>
  <keyword>Filtrum-STI</keyword>
  <keyword>lignin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroenteritis</mesh_term>
    <mesh_term>Enteritis</mesh_term>
    <mesh_term>Adenovirus Infections, Human</mesh_term>
    <mesh_term>Enterovirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

